Global Photosensitizer Drug
Global Photosensitizer Drug

Photosensitizer Drug Comprehensive Study by Type (Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others), Aminolevulinic acid (ALA), Chlorines, Others), Application (Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others), Actinic Keratosis (AK), Psoriasis, Acne, Others), End User (Hospitals, Cosmetics & Dermatology Clinics (C&DC), Cancer Treatment Centers (CCC), Others) Players and Region - Global Market Outlook to 2026

Photosensitizer Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 244 Pages 182 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Photosensitizer Drug Market?

Photosensitizers are the chemical components/drugs which are used along with the light to treat different types of cancers. Photosensitizers absorb the light and change into another form which in turn destroys the cancer cells. Photosensitizer drugs are used in photodynamic therapy for the treatment of cancer. These agents are exposed to a specific wavelength of light to produce an active form of oxygen that kills nearby cancer cells. Various forms of photosensitizer drugs include porphyrin derivatives, Aminolevulinic acid (ALA), chlorines, and others.

The market study is being classified by Type (Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others), Aminolevulinic acid (ALA), Chlorines and Others), by Application (Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others), Actinic Keratosis (AK), Psoriasis, Acne and Others) and major geographies with country level break-up.

Sanofi S.A (France), DUSA Pharmaceuticals, Inc. (United States), Bausch Health Companies Inc. (United States), Beiersdorf AG (Germany), Soligenix, Inc. (United States), Theralase Technologies (Canada), Quest Pharmatech (Canada), Galderma (Switzerland) and Biofrontera (Germany) are some of the key players profiled in the study.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Photosensitizer Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Photosensitizer Drug market by Type, Application and Region.

On the basis of geography, the market of Photosensitizer Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increase in the Prevalence of Cancers
  • Rise in the Burden of Dermatology Disorders
  • Development of Healthcare Infrastructure in Emerging Economies

Market Trend
  • Increasing Awareness among People about Preventive Healthcare

Restraints
  • Side Effects of the Photosensitizer Drug

Opportunities
  • Growing R&D Investment by the Market Players
  • Rising Attention toward New Anti-cancer Therapies

Challenges
  • Strigent Government Rules and Regulations


In Oct 2019, Theralase® Technologies Inc is pleased to announce that the Company has been granted a European Patent for its anti-cancer PDCs, which will issue in due course.


Key Target Audience
Manufacturers of Photosensitizer Drug, Suppliers and Distributors of Photosensitizer Drug, Potential Investors, Market Research Firms, Regulatory Bodies, End-Users and Others

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others)
  • Aminolevulinic acid (ALA)
  • Chlorines
  • Others
By Application
  • Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others)
  • Actinic Keratosis (AK)
  • Psoriasis
  • Acne
  • Others
By End User
  • Hospitals
  • Cosmetics & Dermatology Clinics (C&DC)
  • Cancer Treatment Centers (CCC)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the Prevalence of Cancers
      • 3.2.2. Rise in the Burden of Dermatology Disorders
      • 3.2.3. Development of Healthcare Infrastructure in Emerging Economies
    • 3.3. Market Challenges
      • 3.3.1. Strigent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness among People about Preventive Healthcare
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Photosensitizer Drug, by Type, Application, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Photosensitizer Drug (Value)
      • 5.2.1. Global Photosensitizer Drug by: Type (Value)
        • 5.2.1.1. Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others)
        • 5.2.1.2. Aminolevulinic acid (ALA)
        • 5.2.1.3. Chlorines
        • 5.2.1.4. Others
      • 5.2.2. Global Photosensitizer Drug by: Application (Value)
        • 5.2.2.1. Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others)
        • 5.2.2.2. Actinic Keratosis (AK)
        • 5.2.2.3. Psoriasis
        • 5.2.2.4. Acne
        • 5.2.2.5. Others
      • 5.2.3. Global Photosensitizer Drug by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Cosmetics & Dermatology Clinics (C&DC)
        • 5.2.3.3. Cancer Treatment Centers (CCC)
        • 5.2.3.4. Others
      • 5.2.4. Global Photosensitizer Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Photosensitizer Drug (Price)
      • 5.3.1. Global Photosensitizer Drug by: Type (Price)
  • 6. Photosensitizer Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi S.A (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. DUSA Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Bausch Health Companies Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Beiersdorf AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Soligenix, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Theralase Technologies (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Quest Pharmatech (Canada)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Galderma (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biofrontera (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Photosensitizer Drug Sale, by Type, Application, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Photosensitizer Drug (Value)
      • 7.2.1. Global Photosensitizer Drug by: Type (Value)
        • 7.2.1.1. Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others)
        • 7.2.1.2. Aminolevulinic acid (ALA)
        • 7.2.1.3. Chlorines
        • 7.2.1.4. Others
      • 7.2.2. Global Photosensitizer Drug by: Application (Value)
        • 7.2.2.1. Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others)
        • 7.2.2.2. Actinic Keratosis (AK)
        • 7.2.2.3. Psoriasis
        • 7.2.2.4. Acne
        • 7.2.2.5. Others
      • 7.2.3. Global Photosensitizer Drug by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Cosmetics & Dermatology Clinics (C&DC)
        • 7.2.3.3. Cancer Treatment Centers (CCC)
        • 7.2.3.4. Others
      • 7.2.4. Global Photosensitizer Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Photosensitizer Drug (Price)
      • 7.3.1. Global Photosensitizer Drug by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Photosensitizer Drug: by Type(USD Million)
  • Table 2. Photosensitizer Drug Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others) , by Region USD Million (2015-2020)
  • Table 3. Photosensitizer Drug Aminolevulinic acid (ALA) , by Region USD Million (2015-2020)
  • Table 4. Photosensitizer Drug Chlorines , by Region USD Million (2015-2020)
  • Table 5. Photosensitizer Drug Others , by Region USD Million (2015-2020)
  • Table 6. Photosensitizer Drug: by Application(USD Million)
  • Table 7. Photosensitizer Drug Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others) , by Region USD Million (2015-2020)
  • Table 8. Photosensitizer Drug Actinic Keratosis (AK) , by Region USD Million (2015-2020)
  • Table 9. Photosensitizer Drug Psoriasis , by Region USD Million (2015-2020)
  • Table 10. Photosensitizer Drug Acne , by Region USD Million (2015-2020)
  • Table 11. Photosensitizer Drug Others , by Region USD Million (2015-2020)
  • Table 12. Photosensitizer Drug: by End User(USD Million)
  • Table 13. Photosensitizer Drug Hospitals , by Region USD Million (2015-2020)
  • Table 14. Photosensitizer Drug Cosmetics & Dermatology Clinics (C&DC) , by Region USD Million (2015-2020)
  • Table 15. Photosensitizer Drug Cancer Treatment Centers (CCC) , by Region USD Million (2015-2020)
  • Table 16. Photosensitizer Drug Others , by Region USD Million (2015-2020)
  • Table 17. South America Photosensitizer Drug, by Country USD Million (2015-2020)
  • Table 18. South America Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 19. South America Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 20. South America Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 21. Brazil Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 22. Brazil Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 23. Brazil Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 24. Argentina Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 25. Argentina Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 26. Argentina Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 27. Rest of South America Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 28. Rest of South America Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 30. Asia Pacific Photosensitizer Drug, by Country USD Million (2015-2020)
  • Table 31. Asia Pacific Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 32. Asia Pacific Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 34. China Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 35. China Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 36. China Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 37. Japan Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 38. Japan Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 39. Japan Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 40. India Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 41. India Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 42. India Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 43. South Korea Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 44. South Korea Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 45. South Korea Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 46. Taiwan Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 47. Taiwan Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 48. Taiwan Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 49. Australia Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 50. Australia Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 51. Australia Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 55. Europe Photosensitizer Drug, by Country USD Million (2015-2020)
  • Table 56. Europe Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 57. Europe Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 58. Europe Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 59. Germany Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 60. Germany Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 61. Germany Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 62. France Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 63. France Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 64. France Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 65. Italy Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 66. Italy Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 67. Italy Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 68. United Kingdom Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 69. United Kingdom Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 71. Netherlands Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 72. Netherlands Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 73. Netherlands Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 74. Rest of Europe Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 75. Rest of Europe Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 77. MEA Photosensitizer Drug, by Country USD Million (2015-2020)
  • Table 78. MEA Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 79. MEA Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 80. MEA Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 81. Middle East Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 82. Middle East Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 83. Middle East Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 84. Africa Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 85. Africa Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 86. Africa Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 87. North America Photosensitizer Drug, by Country USD Million (2015-2020)
  • Table 88. North America Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 89. North America Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 90. North America Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 91. United States Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 92. United States Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 93. United States Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 94. Canada Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 95. Canada Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 96. Canada Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 97. Mexico Photosensitizer Drug, by Type USD Million (2015-2020)
  • Table 98. Mexico Photosensitizer Drug, by Application USD Million (2015-2020)
  • Table 99. Mexico Photosensitizer Drug, by End User USD Million (2015-2020)
  • Table 100. Photosensitizer Drug: by Type(USD/Units)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Photosensitizer Drug: by Type(USD Million)
  • Table 111. Photosensitizer Drug Porphyrin Derivatives (PD) (Hematoporphyrin Derivative (HpD), Benzoporphyrin Derivative (BPD), Texaphyrins, Others) , by Region USD Million (2021-2026)
  • Table 112. Photosensitizer Drug Aminolevulinic acid (ALA) , by Region USD Million (2021-2026)
  • Table 113. Photosensitizer Drug Chlorines , by Region USD Million (2021-2026)
  • Table 114. Photosensitizer Drug Others , by Region USD Million (2021-2026)
  • Table 115. Photosensitizer Drug: by Application(USD Million)
  • Table 116. Photosensitizer Drug Cancer (Basal Cell Carcinoma, Non-small Cell Lung Cancer, Head & Neck Cancer, Others) , by Region USD Million (2021-2026)
  • Table 117. Photosensitizer Drug Actinic Keratosis (AK) , by Region USD Million (2021-2026)
  • Table 118. Photosensitizer Drug Psoriasis , by Region USD Million (2021-2026)
  • Table 119. Photosensitizer Drug Acne , by Region USD Million (2021-2026)
  • Table 120. Photosensitizer Drug Others , by Region USD Million (2021-2026)
  • Table 121. Photosensitizer Drug: by End User(USD Million)
  • Table 122. Photosensitizer Drug Hospitals , by Region USD Million (2021-2026)
  • Table 123. Photosensitizer Drug Cosmetics & Dermatology Clinics (C&DC) , by Region USD Million (2021-2026)
  • Table 124. Photosensitizer Drug Cancer Treatment Centers (CCC) , by Region USD Million (2021-2026)
  • Table 125. Photosensitizer Drug Others , by Region USD Million (2021-2026)
  • Table 126. South America Photosensitizer Drug, by Country USD Million (2021-2026)
  • Table 127. South America Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 128. South America Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 129. South America Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 130. Brazil Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 131. Brazil Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 132. Brazil Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 133. Argentina Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 134. Argentina Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 135. Argentina Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 136. Rest of South America Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 137. Rest of South America Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 138. Rest of South America Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 139. Asia Pacific Photosensitizer Drug, by Country USD Million (2021-2026)
  • Table 140. Asia Pacific Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 141. Asia Pacific Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 142. Asia Pacific Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 143. China Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 144. China Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 145. China Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 146. Japan Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 147. Japan Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 148. Japan Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 149. India Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 150. India Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 151. India Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 152. South Korea Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 153. South Korea Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 154. South Korea Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 155. Taiwan Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 156. Taiwan Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 157. Taiwan Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 158. Australia Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 159. Australia Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 160. Australia Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 161. Rest of Asia-Pacific Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 162. Rest of Asia-Pacific Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 164. Europe Photosensitizer Drug, by Country USD Million (2021-2026)
  • Table 165. Europe Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 166. Europe Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 167. Europe Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 168. Germany Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 169. Germany Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 170. Germany Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 171. France Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 172. France Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 173. France Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 174. Italy Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 175. Italy Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 176. Italy Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 177. United Kingdom Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 178. United Kingdom Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 179. United Kingdom Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 180. Netherlands Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 181. Netherlands Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 182. Netherlands Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 183. Rest of Europe Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 184. Rest of Europe Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 185. Rest of Europe Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 186. MEA Photosensitizer Drug, by Country USD Million (2021-2026)
  • Table 187. MEA Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 188. MEA Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 189. MEA Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 190. Middle East Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 191. Middle East Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 192. Middle East Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 193. Africa Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 194. Africa Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 195. Africa Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 196. North America Photosensitizer Drug, by Country USD Million (2021-2026)
  • Table 197. North America Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 198. North America Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 199. North America Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 200. United States Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 201. United States Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 202. United States Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 203. Canada Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 204. Canada Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 205. Canada Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 206. Mexico Photosensitizer Drug, by Type USD Million (2021-2026)
  • Table 207. Mexico Photosensitizer Drug, by Application USD Million (2021-2026)
  • Table 208. Mexico Photosensitizer Drug, by End User USD Million (2021-2026)
  • Table 209. Photosensitizer Drug: by Type(USD/Units)
  • Table 210. Research Programs/Design for This Report
  • Table 211. Key Data Information from Secondary Sources
  • Table 212. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Photosensitizer Drug: by Type USD Million (2015-2020)
  • Figure 5. Global Photosensitizer Drug: by Application USD Million (2015-2020)
  • Figure 6. Global Photosensitizer Drug: by End User USD Million (2015-2020)
  • Figure 7. South America Photosensitizer Drug Share (%), by Country
  • Figure 8. Asia Pacific Photosensitizer Drug Share (%), by Country
  • Figure 9. Europe Photosensitizer Drug Share (%), by Country
  • Figure 10. MEA Photosensitizer Drug Share (%), by Country
  • Figure 11. North America Photosensitizer Drug Share (%), by Country
  • Figure 12. Global Photosensitizer Drug: by Type USD/Units (2015-2020)
  • Figure 13. Global Photosensitizer Drug share by Players 2020 (%)
  • Figure 14. Global Photosensitizer Drug share by Players (Top 3) 2020(%)
  • Figure 15. Global Photosensitizer Drug share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Sanofi S.A (France) Revenue, Net Income and Gross profit
  • Figure 18. Sanofi S.A (France) Revenue: by Geography 2020
  • Figure 19. DUSA Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. DUSA Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 21. Bausch Health Companies Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Bausch Health Companies Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Beiersdorf AG (Germany) Revenue, Net Income and Gross profit
  • Figure 24. Beiersdorf AG (Germany) Revenue: by Geography 2020
  • Figure 25. Soligenix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Soligenix, Inc. (United States) Revenue: by Geography 2020
  • Figure 27. Theralase Technologies (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Theralase Technologies (Canada) Revenue: by Geography 2020
  • Figure 29. Quest Pharmatech (Canada) Revenue, Net Income and Gross profit
  • Figure 30. Quest Pharmatech (Canada) Revenue: by Geography 2020
  • Figure 31. Galderma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Galderma (Switzerland) Revenue: by Geography 2020
  • Figure 33. Biofrontera (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Biofrontera (Germany) Revenue: by Geography 2020
  • Figure 35. Global Photosensitizer Drug: by Type USD Million (2021-2026)
  • Figure 36. Global Photosensitizer Drug: by Application USD Million (2021-2026)
  • Figure 37. Global Photosensitizer Drug: by End User USD Million (2021-2026)
  • Figure 38. South America Photosensitizer Drug Share (%), by Country
  • Figure 39. Asia Pacific Photosensitizer Drug Share (%), by Country
  • Figure 40. Europe Photosensitizer Drug Share (%), by Country
  • Figure 41. MEA Photosensitizer Drug Share (%), by Country
  • Figure 42. North America Photosensitizer Drug Share (%), by Country
  • Figure 43. Global Photosensitizer Drug: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Sanofi S.A (France)
  • DUSA Pharmaceuticals, Inc. (United States)
  • Bausch Health Companies Inc. (United States)
  • Beiersdorf AG (Germany)
  • Soligenix, Inc. (United States)
  • Theralase Technologies (Canada)
  • Quest Pharmatech (Canada)
  • Galderma (Switzerland)
  • Biofrontera (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation